Press monitoring
US agency lifts ban on funding human–animal hybrids
8.8.2016 | Press monitoring
Since September 2015, researchers have been banned from receiving funding from the US National Institutes of Health (NIH) for adding human stem cells to animal embryos, creating blends called chimaeras. But a proposal by the NIH released on 4 August would lift the funding moratorium, except for certain situations. It would also set up a panel to...
Bioreactor brings on-demand portability to biopharmaceutical drug production
5.8.2016 | Press monitoring
By manipulating yeast into producing specific proteins, a new portable device developed at MIT can produce a range of biopharmaceutical drugs on demand. The system would grant remote or on-the-move medical professionals access to vaccines and other therapies that are normally produced in large fermentation plants. At the core of the system is a...
Nottingham Dollies prove cloned sheep can live long and healthy lives
3.8.2016 | Press monitoring
Three weeks after the scientific world marked the 20th anniversary of the birth of Dolly the sheep new research, published by The University of Nottingham, has shown that four clones derived from the same cell line—genomic copies of Dolly—reached their 8th birthdays in good health. Nottingham's Dollies—Debbie, Denise, Dianna and Daisy—have just...
Novel repair system discovered in algae may yield new tools for biotechnology
1.8.2016 | Press monitoring
A new way of fixing inactive proteins has been discovered in an algae, which uses chloroplast extracts and light to release an interrupting sequence from a protein. Research specialist Stephen Campbell and Professor David Stern at the Boyce Thompson Institute report the discovery in the July 29 issue of the Journal of Biological Chemistry. This...
Smart bricks would enable walls capable of generating electricity, clean water
29.7.2016 | Press monitoring
A lot of things are becoming "smart" these days, but bricks might not be something you'd expect to be added to the list. On the way to buildings that act like "large-scale living organisms," scientists at the University of the West of England (UWE Bristol) are developing smart bricks that would make use of microbes to recycle wastewater,...
ObsEva Initiates Phase 1 Clinical Program of OBE022, a First-in-Class Orally Active Prostaglandin F2alpha Antagonist, for the Treatment of Preterm Labor
28.7.2016 | Press monitoring
Geneva, Switzerland, 28 July 2016 - ObsEva , a biopharmaceutical company innovating women's reproductive health and pregnancy therapeutics from conception to birth, announced today the initiation of a Phase 1 clinical program of OBE022, a novel, first-in-class, orally-active, small molecule prostaglandin F 2alpha (PGF 2alpha ) receptor...
Apricus Biosciences Announces Approval of Vitaros(R) for the Treatment of Erectile Dysfunction in Lebanon
27.7.2016 | Press monitoring
SAN DIEGO, July 27, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Republic of Lebanon Ministry of Public Health has granted market approval to Vitaros ® , a topical cream indicated for the treatment of patients with...
Unique Brain Exercise Shown in Study to Lower Risk of Dementia
27.7.2016 | Press monitoring
SAN FRANCISCO, July 27, 2016 (GLOBE NEWSWIRE) -- Researchers announced breakthrough study results Monday -- indicating that a particular form and dose of brain training can reduce the risk of dementia by 48 percent over a ten-year period in cognitively healthy, community-dwelling older adults. The computerized exercise found effective in the study...
Gene reboots stem cells to slow or reverse the aging proces
27.7.2016 | Press monitoring
Aging affects everyone, so it's no surprise that fighting it gets so much attention from scientists. A new study, centering on an embryonic stem cell gene known as Nanog, was found to restore the regenerative properties of adult stem cells, which naturally diminish over time. According to the researchers, this process has the potential to slow...
Adaptimmune Receives Orphan Drug Designation in the European Union for its NY-ESO SPEAR® T-cell Therapy for Treatment of Soft Tissue Sarcoma
26.7.2016 | Press monitoring
PHILADELPHIA and OXFORD, United Kingdom, July 26, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy for treatment of cancer, today announced that the European Commission has designated the company's NY-ESO SPEAR ® T-cell therapy as an orphan medicinal product for the treatment of soft tissue sarcoma,...
